LONDON (ShareCast) - (Sharecast News) - Cell-based therapeutics company ReNeuron Group has signed a research agreement with an unnamed major pharmaceutical company, it announced on Tuesday, to explore the potential use of its proprietary exosomes to deliver novel therapeutics.
The AIM-traded firm said the deal followed its strategy of collaborating with pharmaceutical and biotechnology companies to use its exosome technology as a novel delivery vehicle.

It explained that its exosomes are derived from its 'CTX' neural stem cell line, and had the ability to cross the blood brain barrier and to be manufactured at scale.

The board said the research collaboration would focus on the use of ReNeuron's exosomes for the delivery of gene silencing sequences created by the pharmaceutical company.

ReNeuron would be responsible for manufacturing exosomes, and then loading them with the gene silencing sequences, after which the pharmaceutical company would evaluate the loaded exosomes.

The company would be paid by the pharmaceutical company for manufacturing and loading the exosomes in the initial phase of the collaboration.

It was ReNeuron's second research collaboration, following the signing of an ongoing agreement with a US pharmaceutical company in January 2019.

"We are delighted to have signed this latest exosome research collaboration agreement with an experienced leader in the discovery and development of novel gene silencing-based therapeutics," said chief executive officer Olav Helleb?.

"The collaboration is in line with our strategy of collaborating and then out-licensing our proprietary exosome technology as a novel delivery vector and underlines the potential commercial value of these proprietary nanoparticles generated from our CTX neural stem cell line."

At 1321 BST, shares in ReNeuron Group were up 14.59% at 124.9p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE